The SA Journal Diabetes & Vascular Disease Vol 13 No 2 (December 2016)

10 / 52

RESEARCH ARTICLE SA JOURNAL OF DIABETES & VASCULAR DISEASE
60 VOLUME 13 NUMBER 2 • DECEMBER 2016
17. Teicholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic
volume determinations: echocardiographic-angiopgraphic correlations in the
presence of absence in the presence of absence of synergy. Am J Cardiol 1976;
37: 7–11.
18. Lu B, Song X, Dong X, Yang Y, Zhang Z, Wen J, et al. High prevalence of chronic
kidney disease in population-based patients diagnosed with type 2 diabetes in
downtown Shangai. J Diabetes Complic 2008; 22(2): 96–103.
19. Lemley KV. Diabetes and chronic kidney disease: lessons from the Pima Indians.
Pediatr Nephrol 2008; 23(1): 1933–1940.
20. Das Evcimen N, King GL. The role of protein kinase C activation and the vascular
complications of diabetes. Pharmacol Res 2007; 55(6): 498–510.
21. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic
abnormalities – the role of insulin resistance and the sympathoadrenal system.
N Engl J Med 1996; 334: 374–381.
22. Ritz E. Metabolic syndrome and kidney disease. Blood Purif 2008; 26(1):
59–62.
23. Paravivini TM, Touyz RM. NAD (P) H oxidase, reactive oxygen species, and
hypertension: clinical implications and therapeutic possibilities. Diabetes Care
2008; 31(Suppl. 2): S170–S180.
24. Kis E, Cseprekal O, Horvath Z, Katona G, Fekete BC,Hrapka L, et al . Pulse
pressure velocity in end-stage renal disease: influence of age and body
dimensions. Pediatr Res 2008; 63(1): 95–98.
25. Minutolo R, Borrelli S, Chiodini P, Scigliano R, Bellizzi V, Cianciaruso B, et al.
Effects of age on hypertensive status in patients with chronic kidney disease. J
Hypertens 2007; 25(11): 2325–2333.
26. Laurent S, Boutouyrie P. Arterial Stiffness: a ne surrogate end point for
cardiovascular disease. J Nephrol 2007; 20(Suppl. 12): S45–S50.
27. Sturm G, Kollerits B, Neyer U, Ritz E, Kronenberg F, for the MMKD study group.
Uric acid as a risk factor for progression of non diabetic chronic kidney disease?
The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol 2008; 43(4):
347–352.
28. Nardi E, Cottone S, Mule G, Palermo A, Cusiman P, Cerasola G. Influence of
chronic renal insufficiency on left ventricular diastolic function in hypertensives
without left ventricular hypertrophy. J Nephrol 2007; 20(3): 320–328.
29. Agaba El. Characteristics of type 2 diabetics presenting with end-stage renal
disease at the Jos University Hospital, Nigeria. West Afr J Med 2004; 23(2):
142–145.
30. Alebiosu CO, Odusan O, Familoni OB, Juiyesimi AE. Cardiovascular risk factors
in type 2 diabetic Nigerians with clinical diabetic nephropathy. Cardiovasc J S
Afr 2004; 15(3): 124–128.
31. Kanda T, Wakino S, Hayashi K, Plutzky J. Cardiovascular disease and type 2
diabetes mellitus: Procceeding with caution at a dangerous intersection. J Am
Soc Nephrol 2008; 19: 4–7.
32. Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y. Uric acid,
left ventricular mass index and risk of cardiovascular disease in essential
hypertension. Hypertension 2006; 47(2): 195–202.
33. Ha SK, Park HS, Kim SJ, Park CH, Kim DS, Kim HS. Prevalence and patterns of
left ventricular hypertrophy in patients with predialysis chronic renal failure. J
Korean Med Sci 1998; 13: 488–494.
34. Aje A, Adedeyi AA, Oladapo OO, Dada A, Ogah US, Ojji DB, Falase AD.
Left ventricular patterns in newly presenting Nigerian hypertensives: An
echocardiographic study. BMC Cardiovasc Disorders 2006; 6: 4.
35. Viazzi F, Parodi D, Leoncini G, Parodi A, Falqui V, Ratto E, et al. Serum uric
acid and target organ damage in primary hypertension. Hypertension 2005; 45:
991–996.
36. Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary
Transforming Growth Factor beta and the progression of chronic kidney disease.
Am J Nephrol 2007; 27(5): 435–440.
37. Choncol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, et al.
Relationship of uric acid with progression of kidney disease. Am J Kidney Dis
2007; 50(2): 239–247.
38. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzoli, et al. A role for
uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13: 2888–
2897.
SUSTAINED RELEASE
METABOLICALLY NEUTRAL1
only generic 1,5 mg
sustained release
formulation
R33,192
Dyna Indapamide SR. Each sustained release tablet contains 1,5 mg indapamide. Reg. No.: RSA S3
A42/7.1/0790. NAM NS2 12/7.1/0138. For full prescribing information, refer to the package insert approved
by the Medicines Control Council, 25 November 2011. 1) Weidmann P. Metabolic profile of indapamide
sustained-release in patients with hypertension. Drug Safety 2001;24(15):1155-1165. 2) Department of
Health website. – Accessed 06/06/2016. DIND223/07/2016.
CUSTOMER CARE LINE 0860 PHARMA (742 762)
A Lupin Group Company The effects of caffeine versus maltodextrin during exercise were
observed in patients with type 2 diabetes. Researchers examined
the effects on blood pressure (BP), heart rate (HR) and blood glucose
(BG) levels associated with the intake of caffeine in comparison
to maltodextrin (CHO) during prolonged periods of low-intensity
exercise in patients with type 2 diabetes.
Researchers conducted a pilot study on eight individuals with
type 2 diabetes who were aged 55 ± 10 years. The participants
either received 1 g/kg of CHO or 1.5 mg/kg of caffeine before
undergoing exercise. They then exercised for 40 minutes, executed
at 40% HR reserve, and recovered for 10 minutes.
Their BP and exertion, assessed by the Borg scale, were checked
every two minute, and their BG levels were checked every 10
minutes. The ANOVA test was used for statistical analysis, and a
p -value < 0.05 indicated statistically significant results.
Neither of the treatments produced significant changes in
BP and HR. However, 1.5 mg/kg caffeine significantly reduced
BG levels by 75 mg/dl (65% CI; p < 0.05) as opposed to 1 g/kg
maltodextrin, which produced no significant change in BG levels
during the 40-minute period of exercise.
References
1. Da Silva LA, De Freitas L, Medeiros TE, Osiecki R, Garcia Michel R, Snak AL, et
al. Caffeine modifies blood glucose availability during prolonged low-intensity
exercise in individuals with type-2 diabetes. Colomb Med (Cali); 2014; 45
(2):72-76. eCollection 2014 Apr. PubMed PMID: 25100892.
2.
e&id=16750&catid=1&Itemid=17.
During prolonged low-intensity exercise,
caffeine alters blood glucose levels